ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
ERβ/circAHNAK Axis Inhibits USP10-FMR1 Deubiquitination to Prevent m⁶A-Mediated ADAM17 Decay and Promote Angiogenesis in Clear Cell Renal Cell Carcinoma.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- p300-Mediated H3K18 Lactylation Drives Radiation-Induced Pulmonary Fibrosis via VIRMA-Dependent m6A Modification of GATA3.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrating single-cell analysis and machine learning algorithms to explore lactylation-related molecular mechanisms and therapeutic responses in clear cell renal cell carcinoma and identifying CDT1 as a potential biomarker.Frontiers in endocrinology · 2026Article
- RNA methylation in urological cancers: regulatory logic, biological functions, and clinical relevance.Frontiers in immunology · 2026Review
- ERβ/circAHNAK Axis Inhibits USP10-FMR1 Deubiquitination to Prevent m⁶A-Mediated ADAM17 Decay and Promote Angiogenesis in Clear Cell Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Estrogen receptor β (ERβ), a nuclear hormone receptor, plays multifaceted roles in tumorigenesis, including transcriptional regulation and noncoding RNA signaling. In clear cell renal cell carcinoma (ccRCC), ERβ is frequently overexpressed and associated with enhanced angiogenesis, a hallmark of aggressive tumor progression. However, the mechanisms linking ERβ signaling to the post-transcriptional and post-translational regulation of angiogenic drivers remain poorly defined. In this study, circAHNAK is identified as a direct downstream effector of ERβ and is significantly upregulated in ccRCC tissues. Elevated circAHNAK in ccRCC cells promotes angiogenesis-related phenotypes in HUVECs by stabilizing ADAM17, a metalloprotease known to facilitate tumor angiogenesis. Mechanistically, ERβ enhances circAHNAK expression by transcriptionally activating its host gene. CircAHNAK binds to FMR1, preventing USP10-mediated deubiquitination of FMR1 at Lys593 and thereby accelerating FMR1 proteasomal degradation. In turn, loss of FMR1 impairs the recognition of m⁶A-modified transcripts, thereby blocking METTL14-mediated m⁶A-dependent decay of ADAM17 mRNA. Consequently, ADAM17 accumulates in ccRCC cell-derived exosomes, driving angiogenesis in ccRCC. Overall, these findings define a novel ERβ/circAHNAK/FMR1/ADAM17 axis that integrates USP10-mediated deubiquitination with FMR1-mediated m⁶A modification to promote ADAM17 expression and angiogenesis in ccRCC. Targeting this pathway may represent a promising therapeutic strategy for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.